Heart disease is often linked to high cholesterol, obesity, or lack of exercise. However, there is mounting evidence that suggests that mental health plays a crucial role in cardiovascular well-being. Stress, anxiety, and depression can silently strain the heart, increasing the risk of serious complications.

A recent study, published in Nature Human Behaviour, showed that loneliness has a significant impact on proteins present in a person's blood. For the study, researchers used data from more than 42,000 participants to explore whether the 9.3% who reported social isolation and 6.4% who reported loneliness had different levels of proteins in their blood compared with those who did not. The researchers then studied data that tracked the health of participants over an average 14-year period.

"We found around 90% of these proteins are linked to the risk of mortality," Dr Chun Shen, Fudan University in China, who is also the lead researcher said. "In addition, about 50% of the proteins were linked to cardiovascular disease, type 2 diabetes and stroke," he added.

Dr Shrey Kumar Srivastav, senior consultant at Sharda Hospital, said that subtle symptoms of heart disease, such as fatigue, shortness of breath, swelling in the lower legs, dizziness, and jaw pain, are often overlooked or attributed to stress and ageing. "Women, in particular, may experience atypical signs like extreme fatigue, indigestion, or upper abdominal pain instead of classic chest pain, leading to delayed diagnosis," he added.

Can Mental Health Issues Trigger Heart Diseases?

Chronic stress can trigger harmful cardiovascular effects, including elevated blood pressure, increased heart rate, and inflammation—key contributors to heart disease. Anxiety and depression further impact heart health by disrupting sleep patterns, raising stress hormone levels, and encouraging unhealthy habits like poor diet and inactivity.

Mental health issues like depression and anxiety have a profound impact on the heart. They don’t just affect emotions but can increase inflammation and put extra strain on the cardiovascular system, warns Dr Srivastav.

Certain risk factors, such as obesity and diabetes, disproportionately affect women, making them more vulnerable to heart failure with preserved ejection fraction (HFpEF). However, due to gender-specific symptom variations, heart disease in women often goes undiagnosed for longer.

Obesity is more prevalent in women than men and is a major risk factor for heart failure. Diabetes, too, has a greater impact on women’s heart health, yet diagnosis and treatment delays are common. Addressing this gap requires increasing awareness, training healthcare providers, and promoting early diagnostic tools,” explains Dr Srivastav.

How Can You Protect Your Heart?

A simple yet effective way to support heart health is by committing to a brisk 30-minute walk daily. Walking not only helps regulate blood pressure and manage weight but also improves circulation and reduces stress.

"Regular physical activity, paired with a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins, significantly lowers cardiovascular risks," advises Dr Srivastav.

Heart disease can often go undetected until a major event occurs, making routine screenings essential.

- For women: Begin screenings around age 30 and continue with regular checkups.

- For men: Start screenings at age 35.

Health screenings, including blood pressure checks, cholesterol tests, and electrocardiograms (ECGs), are critical for early detection of silent heart conditions.

The U.S. government's Department of Health and Human Services (HHS) recently announced partnering with the Department of Veterans Affairs (VA) to fast-track the development of psychedelic-assisted therapies to treat veterans living with mental health issues like post-traumatic stress disorder (PTSD), depression, traumatic brain injury (TBI), and more.

After years of interest, 2026 has marked a major policy shift, with the White House, Congress, and the Department of Veterans Affairs (VA) all actively participating in accelerating research into treatments like psilocybin, MDMA, and ibogaine.

“America owes every veteran the best care our nation can provide,” said HHS Secretary Robert F. Kennedy, Jr. “We’re not going to wait while promising treatments sit on the sidelines. Thanks to President Trump’s leadership, HHS and the VA are working together to develop safe, FDA-approved innovations and transition them from research into care so veterans can access the treatments they deserve.”

The collaboration comes as a bipartisan group of lawmakers introduced a new bill in Congress that would require the U.S. Department of Defense to evaluate how ongoing psychedelic research, particularly those involving psilocybin, could benefit service members who are active on duty and veterans transitioning back to civilian life.

“President Trump opened up a world of possibility for treating Veterans and others with mental health conditions, and VA is proud to be part of this important work,” said VA Secretary Doug Collins. “Today’s MOU ensures effective cooperation with HHS as we try to turn research into life-changing treatment.”

Also read: Under HHS's 'Make Hospital Food Healthier' Pledge, Trump Administration Pushes Hospitals To Offer Healthier Food

Initiative To Accelerate Treatments For Mental Illnesses

The initiative was accelerated this year in April when President Donald Trump signed an executive order directing federal agencies to ramp up research, regulatory review, and appropriate patient access ways for psychedelic medicines targeting serious mental illnesses.

According to the White House, the goal is to expand the scope of scientific research while ensuring safety and regulatory requirements, rather than recklessly legalizing psychedelic drugs for general medical use.

Most psychedelic compounds, including psilocybin, MDMA, and ibogaine, remain classified as Schedule I substances under federal law.

Also read: As Part Of Trump’s Great American Recovery Initiative, US Announces 281 Million Funding To Tackle Addiction

Mental Health Challenges Faced By Veterans

Mental health challenges remain one of the most pressing issues U.S. veterans face after their military service. They are prioritised because they face a disproportionately high burden of PTSD, depression, suicide, and traumatic brain injury among former service members.

While conventional treatments, including antidepressants and psychotherapy, help many patients, a substantial number do not achieve lasting relief.

Researchers hope psychedelic-assisted therapy, administered under carefully supervised clinical settings alongside psychotherapy, may offer another option for people who are still struggling despite existing treatments.

Growing Interest In Psychedelic Medicine

The interest in psychedelic medicine has grown rapidly over the past decade. Studies have suggested that MDMA-assisted psychotherapy may help alleviate PTSD symptoms in some patients, while psilocybin-assisted therapy has shown promise for treatment-resistant depression in clinical trials.

These therapies differ from recreational drug use because they involve carefully screened patients, controlled doses, trained therapists, and structured treatment plan and follow-up sessions.

The World Health Organization (WHO) has validated El Salvador for eliminating trachoma, the world's leading infectious cause of blindness, as a public health problem.

El Salvador is the first country in Central America and the second in the Americas to achieve this milestone.

"I congratulate El Salvador on this remarkable achievement. It is a testament to the power of political commitment, strategic investment, and community engagement," said WHO Director-General Dr Tedros Adhanom Ghebreyesus.

"El Salvador's success is a vital step towards our global target of eliminating trachoma worldwide by 2030 and a clear signal that a healthier, more equitable future is within reach," he added.

El Salvador's Journey To Trachoma Elimination

Also read: US Appeals Court Revives Over 500 Tylenol Lawsuits Over Autism Claims

Between 2023 and 2026, El Salvador conducted targeted assessments in communities identified as at higher environmental and social risk. The surveys found no evidence of active trachoma transmission.

As per the WHO, "no cases of active disease were detected in children, and no adults were found to have advanced trachoma capable of causing blindness". These findings confirmed that trachoma is no longer a public health problem in the country, the UN health agency said.

El Salvador's achievement was supported by a coordinated approach that included:

• Strengthening primary healthcare services
• Improving water, sanitation and hygiene (WASH)
• Expanding eye health services, including adult vision screening
• Collaboration between government agencies, communities and international partners

The country has also established trained health personnel, integrated surveillance systems and the capacity to detect and treat trichiasis—the advanced stage of trachoma in which eyelashes turn inward and can lead to blindness.

What Is Trachoma?

Trachoma is a bacterial eye infection caused by Chlamydia trachomatis. It can spread from person to person through contaminated fingers, fomites and flies that could come into contact with discharge from the eyes or nose of an infected person.

Environmental risks like poor hygiene, overcrowded households, and inadequate access to water and sanitation facilities can also lead to trachoma.

Repeated infections can scar the inner eyelid, causing the eyelashes to turn inward—a condition known as trichiasis. Without treatment, the eyelashes scratch the surface of the eye, potentially leading to irreversible blindness.

Read More: Wegovy More Likely To Cause Rare Blindness Than Ozempic And Other Similar Drugs, Recent Study Finds

Trachoma Still Persists In Parts Of The Americas

Although El Salvador has eliminated trachoma as a public health problem, the disease remains endemic in rural and remote areas of Brazil, Colombia, Guatemala and Peru.

WHO recommends that countries maintaining elimination continue surveillance and ensure access to quality eye care services to prevent the disease from re-emerging.

WHO Criteria For Elimination

WHO defines elimination of trachoma as a public health problem based on three key criteria:

• Trichiasis prevalence of less than 0.2% among people aged 15 years and older.
• Active trachoma (trachomatous inflammation–follicular) prevalence of less than 5% among children aged 1–9 years in every previously endemic district.
• A functioning health system capable of identifying and managing new trichiasis cases.

With this achievement, El Salvador joins 64 countries worldwide that have been validated by WHO for eliminating at least one neglected tropical disease. Seven of these countries are in the Americas.

While there is no firm scientific evidence linking Tylenol use during pregnancy to autism, a US federal appeals court has revived more than 500 private lawsuits against the painkiller's maker, Kenvue, over claims that prenatal exposure to acetaminophen contributed to autism and attention-deficit/hyperactivity disorder (ADHD) in children.

The ruling does not determine that Tylenol causes autism or ADHD. Rather, it held that expert testimony supporting the plaintiffs should not have been excluded from the lawsuits.

What Did The US Appeals Court Say

On July 13, the 2nd US Circuit Court of Appeals in Manhattan overturned a December 2024 ruling by US District Judge Denise Cote, who had dismissed the lawsuits after rejecting the methodology of the plaintiffs' expert witnesses.

In its 64-page decision, the three-judge panel said the district court had improperly excluded expert testimony from three doctors presented by parents and guardians seeking to link prenatal Tylenol use with autism and ADHD.

Circuit Judge Guido Calabresi wrote that the experts' methods reflected approaches used by other scientists and "constitute acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree."

Also read: Not Lyme Disease, Canada Sees Rise in Another Tick-Borne Infection As Temperatures Increase

Court Did Not Rule That Tylenol Causes Autism

The appeals court emphasized that it was not deciding whether acetaminophen causes autism or ADHD, nor was it making any public health determination.

Instead, the ruling focused solely on whether the expert testimony met the legal standards required to be considered in court.

The three experts whose testimony was reinstated include:

• Andrea Baccarelli, Dean of Harvard University's School of Public Health
• Eric Hollander, Professor of Psychiatry at Albert Einstein College of Medicine
• Brandon Pearson, Toxicologist at Columbia University

Ashley Keller, a lawyer representing the families, said the panel unanimously found that the experts had reliably applied accepted scientific methods.

Kenvue Defends Tylenol's Safety

Kenvue, which was spun off from Johnson & Johnson in 2023, said it continues to stand by the safety of Tylenol.

"We stand behind the safety of our product and will continue to defend these cases," the company said in a statement.

Several retailers and pharmacy chains—including CVS, Kroger, Target, Walgreens, and Walmart—have also been named as defendants.

Trump Administration's Remarks Sparked Debate

The lawsuits gained attention after President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. issued guidance last year discouraging pregnant women from using acetaminophen, citing it as a possible contributor to autism.

The remarks triggered concern among expectant mothers and prompted criticism from many healthcare experts and medical organizations, which said the evidence does not support such definitive claims.

Is Acetaminophen Linked to Autism or ADHD?

The scientific evidence remains inconclusive. Some observational studies have reported a possible association between prolonged acetaminophen use during pregnancy and an increased risk of autism or ADHD in children. However, many other studies have found no significant link.

Importantly, an association does not prove that acetaminophen causes these conditions. Researchers note that factors such as maternal illness, genetics, underlying medical conditions, and other environmental influences may also affect a child's neurodevelopment.

As a result, experts say more high-quality research is needed before any causal relationship can be established.

What Do Medical Experts Recommend?

Major medical associations continue to consider acetaminophen the preferred pain reliever and fever reducer during pregnancy when used appropriately.

Doctors advise pregnant women to:

• Use the lowest effective dose for the shortest necessary duration.
• Avoid prolonged or unnecessary use without medical advice.
• Consult their healthcare provider before taking any medication during pregnancy.

Medical societies have also cautioned against avoiding acetaminophen altogether, noting that untreated high fever or severe pain during pregnancy can pose risks to both the mother and the developing baby.